Name: An Update on Lung Cancer Targeted Therapies: The Evolution of Personalized Medicine in NSCLC
Uploaded: 2024-08-27T21:58:08+00:00
Duration: 24 min 50 s
Description: &lt;b&gt;Disclaimer:&lt;/b&gt; On August 19, 2024, the FDA approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

Find latest Non-Small Cell Lung Cancer videos · 600+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

An Update on Lung Cancer Targeted Therapies: The Evolution of Personalized Medicine in NSCLC

By University of Miami Sylvester Comprehensive Cancer Center FEATURING Estelamari Rodriguez

519 views

August 27, 2024

Disclaimer: On August 19, 2024, the FDA approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

Comments 0